Management of Metastatic Breast Cancer with SABCS Updates
This program features world-renowned experts who will review the current standard of care for patients with breast cancer, the latest NCCN Guidelines recommendations, and recent clinical research updates.
This program is designed to meet the educational needs of physicians, nurse practitioners, nurses, physician assistants, pharmacists, and other health care professionals who manage patients with breast cancer.
Following this program, participants should be able to:
- Select evidence-based first- and subsequent-line treatment options for patients with metastatic breast cancer based on HR-positive, HER2-negative metastatic breast cancer.
- List the current therapeutic approaches for management of metastatic triple negative breast cancer.
- Outline new and emerging therapeutic options for patients with HER2-negative metastatic breast cancer.
- Integrate recent advances and available clinical data to optimally sequence HER2-targeted agents in the treatment of HER2-positive metastatic breast cancer.
- Optimally manage common toxicities related to the HER2-targeted therapies.
- Outline new and emerging therapeutic options for patients with HER2-positive metastatic breast cancer.
William J. Gradishar, MD
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Hope S. Rugo, MD
UCSF Helen Diller Family Comprehensive Cancer Center
NCCN Medical Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing.
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.
Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.
William J. Gradishar, MD
AstraZeneca Pharmaceuticals LP: Honoraria; Scientific Advisor
Biotheranostics: Honoraria; Scientific Advisor
Daiichi-Sankyo Co.: Honoraria; Scientific Advisor
Eli Lilly and Company: Scientific Advisor
ImmunoGen, Inc.: Honoraria; Scientific Advisor
MacroGenics: Scientific Advisor
Puma Biotechnology: Scientific Advisor
Seattle Genetics, Inc.: Scientific Advisor
Hope S. Rugo, MD
AstraZeneca Pharmaceuticals LP: Grant/Research Support
Ayala Pharmaceuticals: Grant/Research Support
Boehringer Ingelheim GmbH: Grant/Research Support
Daiichi-Sankyo Co.: Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Gilead Sciences, Inc.: Grant/Research Support
MacroGenics: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Mylan Inc.: Honoraria
Napo Pharmaceuticals Inc.: Honoraria
Novartis Pharmaceuticals Corporation: Grant/Research Support
Pfizer Inc.: Grant/Research Support
Polyphor Ltd.: Grant/Research Support
Puma Biotechnology: Honoraria
Roche Laboratories, Inc.: Grant/Research Support
Seattle Genetics, Inc.: Grant/Research Support
Sermonix Pharmaceuticals: Grant/Research Support
NCCN Staff Disclosures
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NCCN designates this educational activity for a maximum of 1.0 contact hour.
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-22-034-H01-P
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until March 15, 2023. PAs should only claim credit commensurate with the extent of their participation.
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
To complete this activity, users will need:
- A device with an Internet connection and sound playback capability
- One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
- Internet Explorer is no longer supported
- Adobe Reader or other PDF reader software for certificate viewing/printing